Compare Gold Fields Limited (GFI) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Moderna, Inc. — how do they compare? Gold Fields Limited trades at $40.23 (market cap $36.07B), while Moderna, Inc. trades at $60.51 (market cap $24.18B). The key difference: Gold Fields Limited is the larger of the two by market cap, and Gold Fields Limited pays a 5.76% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| GFI | MRNA | |
|---|---|---|
Market Cap | $36.07B | $24.18B |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $81.80 |
52-Week Low | $29.31 | $22.36 |
Enterprise Value | $37.51B | $20.33B |
Dividend Yield | 5.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $41.06, down slightly by 0.15% today. The stock shows strong fundamentals with robust profitability (40.76% net margin, 52.33% ROE) and attractive valuation (P/E 10.22, EV/EBITDA 5.92). Recent earnings were mixed with one beat and two misses, but 2025 projections indicate significant growth. Technical indicators show a bullish overall signal despite overbought RSI readings. Institutional interest remains strong with recent acquisitions by major funds.
The outlook for GFI appears positive with projected revenue growth to $8.8B and net income of $3.6B in 2025. Analyst consensus targets $52.00 (24% upside) with no sell ratings. Key risks include gold price volatility and operational challenges in mining operations. The combination of strong fundamentals, institutional support, and growth projections supports a constructive view for long-term investors.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
